This years' conference on Clinical Trials in CNS will bring together leading industry experts to explore the current and future opportunities within CNS drug development. Representing the second largest therapeutic segment of the pharmaceutical market it is also one of the fastest growing. This year SMi Group's conference aims to cover clinical drug discovery activities, new therapeutic targets, as well as effective CNS drug development strategies and problems encountered in clinical trials, with in-depth discussions and case study presentations from the key industry players.

As CNS therapies become more complex and difficult to bring to market, the need to consider issues involved in effective trial design is increasingly important. Key issues include discussion on clinical research- Biomarkers and imaging in CNS; The preclinical to clinical interface; Clinical trials in disease specific therapeutics (with a focus on Alzheimer's, Dementia, Depression & Suicidality); Industry and regulatory viewpoints; understanding and measuring cognition, as well as case study presentations on research consortiums and clinical trial developments.

"Treating neurodegenerative diseases already costs European health services some EUR 72 billion annually. There are few treatments for these conditions and those that are available tend to treat the symptoms rather than the underlying cause. Many of these diseases are linked to age, and the proportion of the European population aged over 65 is likely to rise to 25% by 2030 (from 16% today). The incidence of these conditions, as well as the social and financial costs of treating them, is therefore likely to rise in the coming years."

Brian Cummings, JPND Disease Research

Why should you attend this event?

Key topics under discussion include; • Biomarkers and Imaging techniques in CNS research • Latest developments in neurodegenerative diseases • Overcoming the high rate of attrition in therapeutics • Advanced clinical research methodologies and modelling techniques   • New approaches to identify potential drugs and therapeutic targets • Measuring cognition and mental wellbeing in patients

Hear keynote addresses from:

Our expert speaker line-up also includes:

Alan Lenox-Smith, Senior Clinical Research Physician, Eli Lilly Ruth Itzhaki, Professorial Fellow In Molecular Neurobiology, University Of Manchester Samuel Agus, Global Medical Affairs Director, Neurology, Abbott Pharmaceuticals Mark Smith, Medical Director, AstraZeneca Ion-George Anghelescu, Director of Clinical Science, Johnson & Johnson Sophie Dix, Senior Research Scientist, Eli Lilly  Marie Luby, Post Doctoral Scientist, National Institutes of Health (NIH)  Frank Boess, Senior Clinical Research Scientist, Eli Lilly Hassan Rahmoune, Head of Translational Medicine & Discovery Biomarkers, University of Cambridge Marina Zvartau-Hind, Director of Clinical Neurology, GlaxoSmithKline Kate Shaw, Patient Recruitment Director, Innovative Trials (Formerly of Roche) Chas Bountra, Chief Scientist, Structural Genomics Consortium, University of Oxford Blossom Stephan, Research Associate, Cambridge Neuroscience Richard Porter, R&D Project Leader, Hoffmann-La Roche John Greist, Director, Healthcare Technology Systems

Who should attend?

You should attend this event if you are a Director, Area Head, CSO, or VP from within the Pharmaceutical or Healthcare industry with responsibilities in the following areas:

• CNS Clinical Discovery/Nervous System Research
• Clinical Trial Management and Operation
• CNS Therapeutics and Molecular Profiling
• Neurology/Neuroscience
• Medical Directors
• Pain Research/Management
• Biomarkers and Imaging
• Pre-Clinical/Clinical R&D
• Clinical Pharmacology
• Patient Recruitment
• Translational Medicine
• Biostatistics and Modelling
• Emerging Targets/Lead Optimisation
• Genomics/Bioinformatics/Neuroinformatics
• Any field related to Clinical Research and Clinical Trials in CNS...

Venue details

London Marriott Hotel Regents Park 128 King Henry's Road London NW3 3ST Phone: +44 (0)207 722 7711 Fax: +44 (0)207 586 5822 Sales: +44 (0)207 449 4412 Sales fax: +44 (0)207 722 5973  www.marriott.co.uk/Regents-Park

Ideally located with easy access to London's major motorways, the London Marriott Hotel Regents Park is set in the quiet suburbs of Swiss Cottage; close to Lords Cricket Ground, London Zoo and the chic bars and restaurants of St Johns Wood and Primrose Hill. The nearby tube station offers direct access to Wembley and the O2 Centre, Bond Street, Westminster and Canary Wharf on the Jubilee line.

The only luxury North London hotel in Swiss Cottage, the London Marriott Hotel Regents Park promises a delightful stay, offering spacious rooms graced by amenities both pampering and practical - from luxurious new bedding to wireless Internet access. A tempting choice of dining includes the vibrant flavours of Brasserie Centrale and the casual Chat's Cafe Bar. To stay fit, a well-equipped leisure club and indoor pool awaits.

Nearest train station:
West Hampstead, 1.9 km

Nearest underground station:
Swiss Cottage (Jubilee line), 0.5 km, 5 min walk

Conference Documentation